A Phase IIA Trial of Continuous Five Day Infusions of MSI-1256F (Squalamine Lactate) Plus Carboplatin for Therapy of Refractory and Resistant Stage III and IV Ovarian Cancer

Trial Profile

A Phase IIA Trial of Continuous Five Day Infusions of MSI-1256F (Squalamine Lactate) Plus Carboplatin for Therapy of Refractory and Resistant Stage III and IV Ovarian Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2012

At a glance

  • Drugs Squalamine (Primary) ; Carboplatin
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Dec 2012 Status changed from active, no longer recruiting to completed based on information reported in an Ohr Pharmaceutical media release.
    • 27 Dec 2012 Additional data will be reported in 2013 according to an Ohr Pharmaceutical media release.
    • 22 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top